Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Low Intensity Conditioning Regimens

Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma

Abstract

relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (abmt) for malignant lymphoma (ml). allogeneic transplantation (allosct) is a therapeutic option. however, it is associated with a high incidence of transplant-related organ toxicity and mortality. we recently reported fast engraftment and minimal transplant-related toxicity, using fludarabine-based conditioning with reduced amounts of chemotoxic drugs prior to allosct. we now present our experience with 23 heavily treated high risk ml patients who underwent matched allosct following the same low intensity conditioning. the patients (20 male, three female) were aged 13–63 years. nineteen had nhl and four hd (resistant disease 12, partial remission 11). five were post abmt. twenty-two patients had fully matched sibling donors, and one a fully matched unrelated donor. engraftment was fast. there was no rejection or non-engraftment. organ toxicity was moderate with no liver or renal toxicity >grade ii. four patients developed >grade II graft-versus-host disease (GVHD). Seven patients died – four of grade III–IV GVHD and severe infections, two of bacterial sepsis, one of pulmonary failure. Ten patients are alive after 22.5 (15–37) months. Survival and disease-free survival at 37 months are both 40%. Probability of relapse is 26%. These encouraging results suggest that alloSCT following fludarabine-based low intensity conditioning in high-risk patients merits further evaluation. Bone Marrow Transplantation (2000) 25, 1021–1028.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 1995 333: 1540–1555

    Article  CAS  Google Scholar 

  2. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease. Results of a BNLL randomized trial Lancet 1993 341: 1051–1054

    Article  CAS  Google Scholar 

  3. Stahel RA, Lorenz MJ, Pichert G et al. High-dose chemotherapy and autologous bone marrow transplantation for malignant lymphomas Cancer Treat Rev 1995 21: 3–32

    Article  CAS  Google Scholar 

  4. Stahel RA, Jost LM, Honegger H et al. Randomized trial showing equivalent efficacy of Filgrastim 5μg/kg/d and 10μg/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas J Clin Oncol 1997 15: 1730–1735

    Article  CAS  Google Scholar 

  5. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group Registry Data J Clin Oncol 1992 10: 1690–1695

    Article  CAS  Google Scholar 

  6. Shipp MA . Prognostic factors in aggressive non-Hodgkin's lymphoma: who has ‘high-risk’ disease? Blood 1994 83: 1165–1173

    CAS  PubMed  Google Scholar 

  7. Reece DE, Connors JM, Spinelli JJ et al. Intensive therapy with cyclophosphamide, carmustine, etoposide + cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy Blood 1994 83: 1193–1199

    CAS  PubMed  Google Scholar 

  8. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients Blood 1993 81: 1137–1145

    CAS  PubMed  Google Scholar 

  9. Nagler A, Ackerstein A, Or R et al. Immunotherapy with recombinant human interleukin-2 and recombinant interferon-α in lymphoma patients post-autologous marrow or stem cell transplantation Blood 1997 89: 3951–3959

    CAS  PubMed  Google Scholar 

  10. Slavin S, Nagler A . New developments in bone marrow transplantation Curr Opin Oncol 1991 3: 254–271

    Article  CAS  Google Scholar 

  11. Weiss L, Weigensberg M, Morecki S et al. Characterization of effector cells of graft vs. leukemia following allogeneic bone marrow transplantation in mice inoculated with murine B-cell leukemia Cancer Immunol Immunother 1990 31: 236–242

    Article  CAS  Google Scholar 

  12. Weiss L, Lubin I, Factorowich I et al. Effective graft versus leukemia effects independent of graft versus host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma (BCL1): role of cell therapy and recombinant IL-2 J Immunol 1994 153: 2563–2567

    Google Scholar 

  13. Slavin S, Weiss L, Morecki S et al. Eradication of murine leukemia with histoincompatible marrow grafts in mice conditioned with total lymphoid irradiation (TLI) Cancer Immunol Immunother 1981 11: 155–158

    Article  Google Scholar 

  14. Or R, Nagler A, Ackerstein A et al. Allogeneic cell-mediated immunotherapy at the minimal residual disease stage following autologous stem cell transplantation for malignant lymphoma Immunother 1998 21: 447–453

    Article  CAS  Google Scholar 

  15. Papadopoulos EB, Landanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein–Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation New Engl J Med 1994 330: 1185–1191

    Article  CAS  Google Scholar 

  16. Toren A, Or R, Ackerstein A, Nagler A . Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT) Bone Marrow Transplant 1997 20: 67–69

    Article  CAS  Google Scholar 

  17. Slavin S, Nagler A . Immunotherapy in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma Ann Oncol 1998 9: S31–39

    Article  Google Scholar 

  18. Phillips GL, Herzig RH, Lazarus HM et al. High dose chemotherapy, fractionated total body irradiation and allogeneic marrow transplantation for malignant lymphoma J Clin Oncol 1986 4: 480–498

    Article  CAS  Google Scholar 

  19. Jones RJ, Ambinder RF, Piantadosi S, Santos GW . Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 1991 77: 649–653

    CAS  PubMed  Google Scholar 

  20. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma Blood 1994 84: 1050–1055

    CAS  PubMed  Google Scholar 

  21. Verdonck LF, Dekker AW, Lokhorts HM et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma Blood 1997 90: 4201–4205

    CAS  Google Scholar 

  22. Demirer T, Weaver CH, Buckner CD et al. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy J Clin Oncol 1995 13: 596–602

    Article  CAS  Google Scholar 

  23. Van Besien W, Mehra RC, Giralt SA et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology Am J Med 1996 100: 299–307

    Article  CAS  Google Scholar 

  24. Gajewski JL, Phillips GL, Sobocinski KA et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease J Clin Oncol 1996 14: 572–578

    Article  CAS  Google Scholar 

  25. Milpied N, Fielding AK, Pearce RM et al. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation J Clin Oncol 1996 14: 1291–1296

    Article  CAS  Google Scholar 

  26. De Lima M, Van Besien KW, Giralt SA et al. Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma Bone Marrow Transplant 1997 19: 121–127

    Article  CAS  Google Scholar 

  27. Dann EJ, Daugherty CK, Larson RA . Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma Bone Marrow Transplant 1997 20: 369–374

    Article  CAS  Google Scholar 

  28. Yang SW, Huang P, Plunkett W . Dual mode of inhibition of purified DNA ligase I from human cells by 9-β-D-arabinofuranosyl-2-fluoroadenine triphosphate J Biol Chem 1992 267: 2345–2349

    CAS  PubMed  Google Scholar 

  29. Huang P, Plunkett W . Action of 9-β-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism Mol Pharmacol 1991 39: 449–455

    CAS  PubMed  Google Scholar 

  30. Robertson LE, Chubb S, Meyn RE . Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinofuranosyl-2-fluoroadenine Blood 1993 81: 143–150

    CAS  PubMed  Google Scholar 

  31. Keating MJ . Fludarabine phosphate: current and future therapeutic applications Semin Oncol 1993 20: 1–31

    PubMed  Google Scholar 

  32. Keating MJ, Kantarjian H, O'Brien S et al. Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia J Clin Oncol 1991 9: 44–49

    Article  CAS  Google Scholar 

  33. Keating MJ, Kantarjian H, Talpaz M et al. Fludarabine: a new agent with major activity against chronic lymphocytic leukemia Blood 1989 74: 19–25

    CAS  PubMed  Google Scholar 

  34. Redman JR, Cabanillas F, Velasquez WS et al. Phase II trial of fludarabine phosphate in lymphoma: an effective new agent in low-grade lymphoma J Clin Oncol 1992 10: 790–794

    Article  CAS  Google Scholar 

  35. Hochster HS, Kim K, Green MD et al. Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study J Clin Oncol 1992 10: 28–32

    Article  CAS  Google Scholar 

  36. Hiddemann W, Unterhalt M, Port C et al. Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin's lymphoma: a phase II study of the German Low-Grade Non-Hodgkin's Lymphoma Study Group Semin Oncol 1993 20: 28–31

    CAS  PubMed  Google Scholar 

  37. Pigaditou A, Rohatiner AZS, Whelan JS et al. Fludarabine in low-grade lymphoma Semin Oncol 1993 20: 24–27

    CAS  PubMed  Google Scholar 

  38. Keating MJ . Immunosuppression with purine analogues – the flip side of the gold coin Ann Oncol 1993 4: 347–348

    Article  CAS  Google Scholar 

  39. Aversa F, Tabilio A, Velardi A et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype New Engl J Med 1998 339: 1186–1193

    Article  CAS  Google Scholar 

  40. Slavin S, Nagler A, Naparstek E . Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763

    CAS  PubMed  Google Scholar 

  41. Or R, Weiss L, Teiman S, Polliack A . Fludarabine monophosphate reduces the incidence and severity of graft-versus-host disease in a murine model of bone marrow transplantation Blood 1997 1: 471–472 (letter)

    Google Scholar 

  42. Gribben JG, Freedman AS, Woo SD et al. All advanced non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment Blood 1991 78: 3275–3280

    CAS  PubMed  Google Scholar 

  43. Pugatsch T, Oppenheim A, Slavin S . Improved single step PCR assay for sex identification post allogeneic sex-mismatched BMT Bone Marrow Transplant 1996 17: 273–275

    CAS  PubMed  Google Scholar 

  44. Nakamura Y, Leppert M, O'Connell P . Variable number of tandem repeat (VNTR) markers for human gene mapping Science 1987 235: 1616–1622

    Article  CAS  Google Scholar 

  45. Przepiorka DM, Weisdorf D, Martin P . Consensus conference on acute GVHD grading Bone Marrow Transplant 1995 15: 825–828

    CAS  PubMed  Google Scholar 

  46. Sullivan KM, Agura E, Anasetti C . Chronic graft-versus-host disease and other late complications of bone marrow transplantation Semin Oncol 1991 28: 250–259

    CAS  Google Scholar 

  47. Bearman SI, Appelbaum FR, Buckner CD . Regimen related toxicity in patients undergoing bone marrow transplantation Clin Oncol 1988 6: 1562–1568

    Article  CAS  Google Scholar 

  48. Kaplan E, Meier P . Non-parametric estimation from incomplete observations J Am Stat Assoc 1958 54: 457–481

    Article  Google Scholar 

  49. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation Blood 1996 87: 2195–2204

    CAS  Google Scholar 

  50. Nilsson SK, Dooner MS, Tiarks CY et al. Potential and distribution of transplanted hematopoietic stem cells in a nonablated mouse model Blood 1997 89: 4013–4020

    CAS  PubMed  Google Scholar 

  51. Rao SS, Peters SO, Crittenden RB et al. Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment Exp Hematol 1997 25: 114–121

    CAS  PubMed  Google Scholar 

  52. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-vs.-leukemia without myeloablative therapy Blood 1997 89: 4531–4536

    CAS  PubMed  Google Scholar 

  53. McSweeney PA, Wagner JL, Maloney DG et al. Outpatient PBSC allografts using immunosuppression after low-dose TBI before, and cyclosporine (CSP) and mycophenolate mofetil (MMF) after transplant Blood 1998 92: (Suppl.1) 519a (Abstr.2133)

    Google Scholar 

  54. Woolfrey AE, Nash RA, Frangoul HA et al. Non-myeloablative transplant regimen used for induction of multi-lineage allogeneic hematopoietic mixed donor-host chimerism in patients with T cell immunodeficiency Blood 1998 92: (Suppl.1) 520a (Abstr.2135)

    Google Scholar 

  55. Juckett M, Rowlings P, Hessner M et al. T cell-depletedallogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up Bone Marrow Transplant 1998 21: 893–899

    Article  CAS  Google Scholar 

  56. Sykes M, Preffer F, McAfee S et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation Lancet 1999 353: 1755–1759

    Article  CAS  Google Scholar 

  57. Falkenburg JHF, Jluin-Nelemans HC . Mismatched transplants for refractory lymphoma? Lancet 1999 353: 1725–1726

    Article  CAS  Google Scholar 

  58. Aizawa S, Sado T . Graft-versus-leukemia effect in MHC-compatible and incompatible allogeneic bone marrow transplantations of radiation-induced leukemia-bearing mice Transplantation 1991 51: 885–889

    Article  Google Scholar 

  59. Sykes M, Sachs DH . Genetic analysis of anti-leukemic effect of mixed allogeneic bone marrow transplantation Transplant Proc 1989 21: 3022–3024

    CAS  PubMed  Google Scholar 

  60. Mandigers CM, Raemaekers JM, Schattenberg AV et al. Allogeneic bone marrow transplantation with T-cell-depleted marrow grafts for patients with poor-risk relapsed low-grade non-Hodgkin's lymphoma Br J Haematol 1998 100: 198–206.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the Baxter Healthcare Corporation, The Gabriella Rich Foundation, Schering AG, and Fresenius AG, for their support of our ongoing basic and clinical research. We also wish to thank Mr and Mrs Melvin Cohen for their generosity in supporting our clinical research.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nagler, A., Slavin, S., Varadi, G. et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 25, 1021–1028 (2000). https://doi.org/10.1038/sj.bmt.1702392

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1702392

Keywords

Search

Quick links